Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1989-3-22
|
pubmed:abstractText |
From April 1985 to September 1987, 92 patients with advanced NSCLC were randomized to receive cytotoxic chemotherapy, Arm A (treated), or supportive care, Arm B (control). Chemotherapy consisted of the CEP combination (cyclophosphamide 500 mg/m2 i.v. day 1; epirubicin 50 mg/m2 i.v. day 1; cisplatin 80 mg/m2 i.v. day 1) alternated every 4 weeks with the MEC' combination (methotrexate 30 mg/m2 i.v. day 1; etoposide 200 mg/m2 i.v. day 1; CCNU 70 mg/m2 per os, day 1) until progression. Eight-nine patients (44 treated and 45 controls) were eligible for survival and 77 evaluable for response (38 treated and 39 controls). Response rate was: in Arm A, 8/38 (21%) partial response, 20/38 (53%) stable disease and 10/38 (26%) progressive disease; in Arm B, 18/39 (46%) stable disease and 21/39 (54%) progressive disease. Median time to progression was 4 months (range = 1-14) for treated and 2 months (range = 1-9) for controls (P = 0.001). Median survival was 8.5 months (range = 1+ to 25) for Arm A versus 5 months (range = 1+ to 28+) for Arm B; this difference was not statistically significant (Breslow test: chi-square = 2.75, P = 0.097; Mantel-Cox: chi-square = 0.32, P = 0.56). Treatment related toxicity was gastrointestinal WHO grade 3 in 22/102 (22%) CEP courses and in 10/91 (11%) MEC' courses respectively. Other observed side-effects were not clinically important. From these data our treatment was not clearly superior to supportive care in prolonging survival. This suggests the need for the inclusion of a control group in future chemotherapeutic trials of NSCLC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Lomustine,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0277-5379
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1839-43
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2851443-Adult,
pubmed-meshheading:2851443-Aged,
pubmed-meshheading:2851443-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2851443-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:2851443-Cisplatin,
pubmed-meshheading:2851443-Clinical Trials as Topic,
pubmed-meshheading:2851443-Cyclophosphamide,
pubmed-meshheading:2851443-Epirubicin,
pubmed-meshheading:2851443-Etoposide,
pubmed-meshheading:2851443-Female,
pubmed-meshheading:2851443-Humans,
pubmed-meshheading:2851443-Lomustine,
pubmed-meshheading:2851443-Lung Neoplasms,
pubmed-meshheading:2851443-Male,
pubmed-meshheading:2851443-Methotrexate,
pubmed-meshheading:2851443-Middle Aged,
pubmed-meshheading:2851443-Prospective Studies,
pubmed-meshheading:2851443-Random Allocation
|
pubmed:year |
1988
|
pubmed:articleTitle |
Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment.
|
pubmed:affiliation |
Clinica Oncologica, Università di Ancona, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|